Prima BioMed Second Quarter Highlights and Management Conference Call
January 29, 2014 08:05 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Jan 29, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today released its Appendix 4C - Quarterly Report for the...
Prima BioMed's CAN-004 Clinical Trial Amendment Approved in Belgium
January 17, 2014 08:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Jan 17, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company") today announced that the amended CAN-004 protocol was approved by the Belgian...
Expert Panel to Discuss Prima BioMed's CVac Clinical Trial Data in Ovarian Cancer
November 25, 2013 19:30 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Nov 25, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") announced that its recently reported CVac clinical trial...
Prima BioMed's CEO to Present at 11th Annual Commercial Translation of Regenerative Medicine Meeting
November 19, 2013 19:30 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Nov 19, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today announced that its Chief Executive Officer, Matthew...
Prima BioMed Updates CVac Development Program; Clinical Trial Focus on Second-Remission Ovarian Cancer Patient Population
November 11, 2013 07:05 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Nov 11, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company"), in its most recent quarterly call, provided significant...
Prima BioMed and Neopharm Ltd Enter Into License for CVac in Israel
November 06, 2013 07:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Nov 6, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") is pleased to announce that it has entered into a...
Prima BioMed First Quarter Report, Management Conference Call and CVac Program Update
October 31, 2013 18:30 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Oct 31, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") yesterday released its Appendix 4C - Quarterly Report for...
Prima BioMed Management Presentation of CVAC(TM) Phase 2 Trial Results
September 30, 2013 19:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Sep 30, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") announced that management will deliver a presentation of...
Top-Line Analysis of CVac(TM) Phase 2 Trial; Ovarian Cancer Clinical Development Update
September 18, 2013 07:30 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Sep 18, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today announced top-line analysis of the CAN-003 phase 2...
Prima BioMed to Present at WDM Capital 1st Global Life Sciences Conference in Warsaw
September 11, 2013 00:30 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Sep 11, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") has announced today that Marc Voigt, its Chief Financial...